Riastap
Biological
CSL Behring
Total Payments
$65,555
Transactions
11
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $65,555 | 11 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $65,507 | 10 | 99.9% |
| Education | $47.52 | 1 | 0.1% |
Payments by Type
Research
$65,507
10 transactions
General
$47.52
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | CSL Behring | $45,507 | 0 |
| A Program to Evalute Riastap and FIBTERM for the Early Control and Treatment of Postpartum Hemorrhage | CSL Behring | $20,000 | 0 |
Top Doctors Receiving Payments for Riastap
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $65,507 | 10 |
| Charles Greenberg | Hematology | Charleston, SC | $47.52 | 1 |
Ad
Manufacturing Companies
- CSL Behring $65,555
Product Information
- Type Biological
- Total Payments $65,555
- Total Doctors 1
- Transactions 11
About Riastap
Riastap is a biological associated with $65,555 in payments to 1 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2017. In 2017, $65,555 was paid across 11 transactions to 1 doctors.
The most common payment nature for Riastap is "Unspecified" ($65,507, 99.9% of total).
Riastap is associated with 2 research studies, including "An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency" ($45,507).